关于注销 2020 年及 2021 年股票期权激励计划 股票期权的公告 证券代码：603882 证券简称：金域医学 公告编号：2025-023 广州金域医学检验集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 4 月 25 日，广州金域医学检验集团股份有限公司（以下简称"公司" 或"金域医学"）第四届董事会第六次会议审议通过了《关于注销 2020 年及 2021 年股票期权激励计划股票期权的议案》，现将有关事项公告如下： 一、股票期权激励计划的相关信息披露 （一）2020 年股票期权激励计划 1、公司于 2020 年 8 月 17 日召开的第二届董事会第十六次会议及于 2020 年 9 月 2 日召开的 2020 年第三次临时股东大会审议通过了《关于公司<2020 年 股票期权激励计划（草案）>及其摘要的议案》（以下简称"《2020 年股票期权激 励计划》"）、《关于制定<2020 年股票期权激励计划实施考核管理办法>的议案》 和《关于提请股东大会授权董事会办理公司股票期权激励计划 ...

一、管理层的责任 金域医学管理层的责任是按照《上海证券交易所股票上市规则》 和《上海证券交易所上市公司自律监管指南第2号——业务办理》的 相关规定编制营业收入扣除情况表，确保营业收入扣除情况表真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 鉴证报告第 1 页 二、注册会计师的责任 广州金域医学检验集团股份有限公司 营业收入扣除情况表鉴证报告 2024 年度 关于广州金域医学检验集团股份有限公司2024年度 营业收入扣除情况表的鉴证报告 信会师报字[2025]第ZA12081号 广州金域医学检验集团股份有限公司全体股东： 我们审计了广州金域医学检验集团股份有限公司(以下简称"金 域医学")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母 公司资产负债表、2024 年度合并及母公司利润表、合并及母公司现 金流量表、合并及母公司所有者权益变动表和相关财务报表附注，并 于 2025 年 4 月 25 日出具了报告号为信会师报字(2025)第 ZA12078 号 的无保留意见审计报告。 在对上述财务报表执行审计的基础上，我们接受委托，对后附的 金域医学2024年度营业收入扣除情况表 ...

广州金域医学检验集团股份有限公司 审计报告及财务报表 二○二四年度 广州金域医学检验集团股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-110 | 审计报告 信会师报字[2025]第 ZA12078 号 广州金域医学检验集团股份有限公司全体股东： 一、 审计意见 我们审计了广州金域医学检验集团股份有限公司（以下简称金域 医学）财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债 表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方 ...

信会师报字[2025]第 ZA12079 号 广州金域医学检验集团股份有限公司 内部控制审计报告 2024 年度 内部控制审计报告 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内部控制审计报告 第 1 页 四、财务报告内部控制审计意见 我们认为，贵公司于 2024 年 12 月 31 日按照《企业内部控制基 本规范》和相关规定在所有重大方面保持了有效的财务报告内部控 制。 广州金域医学检验集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了广州金域医学检验集团股份有限公司（以下简称 贵公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是贵公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计 ...

Product Innovation and Development - In 2024, the company achieved significant results in product innovation and service enhancement, focusing on high-sensitivity testing products and integrated solutions for complex diseases [3]. - The company launched the first large model in the medical testing industry, "Yujian Yiyan," and successfully integrated it with DEEPSEEK, showcasing advancements in AI technology application [4]. - The company launched several innovative products, including a high-sensitivity detection product for colorectal cancer and a PNH clone detection scheme with a sensitivity of 99.9% [47]. - The company developed a cost-effective early screening project for Alzheimer's disease, targeting a larger elderly population [47]. - The company has developed over 90 types of medical testing and AI technologies, enhancing the sensitivity of autoimmune brain antibody detection from 78% to 95% [84]. - The company achieved a 2.94% year-on-year increase in specimen testing volume, maintaining a leading market share [75]. - The company has established a product system covering "full lifecycle, all disease areas, and all diagnosis and treatment processes" [85]. Financial Performance - The company reported a significant increase in revenue, reaching $1.5 billion, representing a 20% year-over-year growth [22]. - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion RMB in the last quarter [20]. - The company achieved a revenue of ¥7,189,544,739.91, a decrease of 15.81% year-on-year, and a net profit attributable to shareholders of -¥381,241,138.69, a decrease of 159.26% year-on-year [91]. - The company provided a future outlook with a revenue guidance of 1.5 billion RMB for the next quarter, representing a 25% increase [20]. - The company reported a significant increase in user data, with a year-over-year growth of 25% in active users [142]. - The company provided a positive outlook for the next quarter, projecting a revenue increase of 20% to 1.8 billion yuan [140]. Market Expansion and Strategy - The company is expanding its market presence with plans to open 10 new laboratories across major cities in China by the end of the year [20]. - Market expansion plans include entering three new countries by the end of the fiscal year, targeting a 15% increase in international sales [23]. - The company is actively pursuing digital transformation to build a "Medical Testing 4.0" system, focusing on data-driven new productivity [61]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million earmarked for potential deals [137]. - The company is exploring new business models through data monetization and predictive disease modeling, aiming to create new value points in the industry [117]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 15% through efficiency improvements in logistics and supply chain management [20]. - The company achieved a gross margin of 60%, an increase from 55% in the previous quarter, indicating improved operational efficiency [22]. - The company is focused on enhancing its governance framework, as shown by the revisions to its articles of association and meeting rules [132]. - The company plans to enhance operational efficiency through a centralized management system and advanced tools, aiming for automated and intelligent production [120]. - The company has set a goal to improve operational efficiency, targeting a 10% reduction in costs by the end of the fiscal year [137]. Customer Engagement and Satisfaction - The registered users of the one-stop customer service platform KMC exceeded 570,000, indicating strong user engagement and service adoption [4]. - Customer satisfaction ratings improved to 90%, reflecting the effectiveness of new service strategies implemented [21]. - The company upgraded its customer service system, focusing on standardization, differentiation, and intelligent capabilities to enhance service efficiency and quality [49]. Research and Development - Investment in R&D increased by 30%, focusing on innovative testing technologies and services [21]. - The company is investing $50 million in R&D for new technologies aimed at enhancing diagnostic capabilities [22]. - The company has a data platform managing over 23 PB of medical big data, with a growth rate of 1 PB per year, providing a competitive advantage in data service [87]. - The company has established a high-quality talent pool through various training programs, adding 1,190 new courses in 2024, including 1,005 online courses [90]. Corporate Governance and Shareholder Engagement - The company held three shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority investors [128]. - The board of directors convened nine meetings to review major company matters, enhancing governance and decision-making processes [128]. - The company approved several resolutions in its annual general meeting, including financial reports and profit distribution plans for 2023 [131]. - The company has undergone changes in its board and management structure, with new appointments effective from September 27, 2024, indicating a strategic refresh [135]. Social Responsibility and Public Welfare - The company has engaged in public welfare activities across over 20 provinces, benefiting approximately 10,000 individuals through cancer early screening initiatives [5]. - The company invested a total of CNY 28.72 million in social responsibility projects, including CNY 20.64 million in cash donations and CNY 8.07 million in material support [193]. - The company constructed 182 medical laboratories across 140 poverty-stricken counties, investing 11.6681 million yuan to enhance local medical testing and pathology services [195]. - The company actively participated in initiatives like "Thousand Enterprises Helping Thousand Towns" and "Guangzhou Private Enterprises Supporting Rural Revitalization" in key areas of Guizhou Province [196].

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,466,504,705.88, a decrease of 20.35% compared to the same period last year[6] - The net profit attributable to shareholders was -¥27,785,254.88, representing a decline of 49.09% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥38,700,504.33, down 32.11% year-on-year[6] - The basic and diluted earnings per share were both -¥0.06, a decrease of 50.00% year-on-year[6] - Net profit for Q1 2025 was a loss of ¥34,725,978.18, compared to a loss of ¥26,419,413.39 in Q1 2024, representing a 31.5% increase in losses[30] - The total comprehensive income for Q1 2025 was a loss of ¥36,660,342.17, compared to a loss of ¥26,338,875.79 in Q1 2024[31] Cash Flow - The net cash flow from operating activities was ¥54,504,692.15, a significant increase of 139.41% compared to the previous year[6] - The net cash flow from operating activities for Q1 2025 was ¥54,504,692.15, a significant improvement from a negative cash flow of ¥138,310,819.32 in Q1 2024[36] - The net cash flow from investing activities was -97,426,897.49, compared to -97,210,373.11 in the previous period, indicating a slight increase in cash outflow[37] - Cash inflow from financing activities totaled 27,458,021.55, down from 65,159,738.92, reflecting a significant decrease of approximately 58%[37] - Cash outflow for financing activities was 429,632,269.24, compared to 174,788,077.20 in the previous period, representing an increase of about 145%[37] - The net cash flow from financing activities was -402,174,247.69, worsening from -109,628,338.28 in the previous period[37] - The impact of exchange rate changes on cash and cash equivalents was -1,510,271.71, contrasting with a positive impact of 203,344.80 previously[37] - The net increase in cash and cash equivalents was -446,606,724.74, compared to -344,946,185.91 in the previous period, indicating a larger decline[37] - The ending balance of cash and cash equivalents was 1,975,917,824.88, down from 2,104,727,955.32, reflecting a decrease of approximately 6%[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,854,909,916.16, a decrease of 5.17% from the end of the previous year[6] - The company's current assets totaled ¥6,818,528,334.74, down from ¥7,318,237,550.29, indicating a decrease of about 6.86%[22] - The cash and cash equivalents decreased to ¥1,987,068,521.84 from ¥2,433,585,245.93, reflecting a decline of approximately 18.36%[21] - Accounts receivable stood at ¥4,321,276,982.00, slightly down from ¥4,396,328,960.56, showing a decrease of about 1.70%[21] - The total liabilities decreased to ¥2,837,464,947.26 from ¥2,916,821,149.44, which is a reduction of approximately 2.71%[24] - The company's non-current liabilities totaled ¥690,242,205.53, a slight increase from ¥684,406,029.88, indicating a rise of about 0.12%[24] - The total equity remained stable at ¥7,017,444,968.90, unchanged from the previous period[24] - The total equity attributable to shareholders of the parent company decreased to ¥6,887,883,046.28 from ¥7,325,269,947.15, reflecting a decline of 6.0%[25] - As of March 31, 2025, the total assets of the company amounted to ¥9,854,909,916.16, a decrease from ¥10,391,893,742.49 as of December 31, 2024, representing a decline of approximately 5.14%[21] Operational Efficiency and Strategy - The gross profit margin increased by 1.16 percentage points compared to the previous year[7] - The company is focusing on long-term development through differentiated services and cost leadership strategies to enhance competitiveness[7] - The company aims to improve operational efficiency through digital transformation and automation in production processes[7] - Research and development expenses for Q1 2025 were ¥77,105,975.66, down 16.3% from ¥92,123,715.26 in Q1 2024[29] - The company has invested ¥4,236,639.48 in development expenditures, up from ¥3,354,408.43, indicating an increase of about 26.19%[23] - The company’s goodwill remained constant at ¥52,205,371.01, with no change from the previous reporting period[23] Accounting Standards - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[38]

证券代码：603882 证券简称：金域医学公告编号：2025-016 广州金域医学检验集团股份有限公司 二、董事会会议审议情况 广州金域医学检验集团股份有限公司董事会 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以记名投票表决方式通过以下决议： （一）审议通过《广州金域医学检验集团股份有限公司市值管理制度》 经审议，为加强公司市值管理工作，进一步规范公司市值管理行为，维护公司、投资者及其他利益相关 者的合法权益，董事会同意公司依据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海 证券交易所股票上市规则》、《上市公司监管指引第10号一一市值管理》及其他法律、法规及规范性文 件的规定，制定《广州金域医学检验集团股份有限公司市值管理制度》。 表决结果：9 票同意，占公司全体董事人数的100%，0票反对，0票弃权。 特此公告。 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第五次会议于2025 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-016 （一）审议通过《广州金域医学检验集团股份有限公司市值管理制度》 经审议，为加强公司市值管理工作，进一步规范公司市值管理行为，维护公 司、投资者及其他利益相关者的合法权益，董事会同意公司依据《中华人民共和 国公司法》、《中华人民共和国证券法》、《上海证券交易所股票上市规则》、《上市 公司监管指引第 10 号——市值管理》及其他法律、法规及规范性文件的规定， 制定《广州金域医学检验集团股份有限公司市值管理制度》。 表决结果：9 票同意，占公司全体董事人数的 100%，0 票反对，0 票弃权。 广州金域医学检验集团股份有限公司 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第 五次会议于 2025 年 4 月 17 日以通讯方式召开，会议通知已于 2025 年 4 月 10 日以电子形式发出。会议由董事长梁耀铭先生主持，本次会议应出席董事 9 ...

重要内容提示: 公司控股股东、实际控制人梁耀铭先生直接持有公司股份 74,191,907 股，占公司总股本的 16.02%。本次解除质押股份 6,550,000 股，占梁耀铭先生 直接持有公司股份数的 8.83%，占公司总股本的 1.41%。 本次股份解除质押后，公司控股股东、实际控制人梁耀铭先生及其一致 行动人严婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及 锐致累计质押 31,580,000 股，占其持有公司股份总数的 19.14%，占公司总股本 的 6.82%。 一、上市公司股份解除质押 广州金域医学检验集团股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日接到公司控股股东、实际控制人梁耀铭先生通知，获悉其质押给中信证券股份 有限公司的部分公司股份已办理解除质押手续，具体事项如下： | 股东名称 | 梁耀铭 | | --- | --- | | 本次解除质押股份（股） | 6,550,000 | | 占其所持股份比例 | 8.83% | | 占公司总股本比例 | 1.41% | | 解除质押时间 | 2025 年 4 月 7 日 | | 持股数量（股） | 74,191,90 ...